Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Anna Housman

Physician Assistant, Medical Bristol, CT Physician Assistant

NPI 1609161694 CMS profile 11011734

25 Newell Rd Ste E36, Bristol, CT 06010

Open in the dashboard

General payments

$6,023

233 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anna Housman of Bristol, CT is reported in the CMS Open Payments database as having received $6,023 across 233 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,861 71
2024 General $1,619 74
2023 General $1,221 47
2022 General $1,141 32
2021 General $181 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anna Housman
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Anna Housman were reported at $1,861. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Anna Housman Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $181 $156 $41–$563 $132
2022 $1,141 $185 $55–$649 $149
2023 $1,221 $199 $58–$717 $160
2024 $1,619 $206 $62–$740 $164
2025 $1,861 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Salix Pharmaceuticals, a division of Bausch Health US, LLC $792 36 payments
  2. AbbVie, Inc. $738 45 payments
  3. Madrigal Pharmaceuticals $616 10 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $576 23 payments
  5. Ardelyx, Inc. $465 25 payments
  6. Janssen Biotech, Inc. $276 11 payments
  7. Celgene Corporation $273 13 payments
  8. AstraZeneca Pharmaceuticals LP $233 2 payments
  9. Novo Nordisk Inc $232 2 payments
  10. Genzyme Corporation $222 8 payments
  11. Other $1,599 58 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,891 228 payments
  2. Education $132 5 payments
Products named General payments · program years 2021–2025
  1. XIFAXAN $700 29 payments
  2. ZEPOSIA $471 16 payments
  3. IBSRELA $465 25 payments
  4. ENTYVIO $447 19 payments
  5. REZDIFFRA $429 8 payments
  6. RINVOQ $409 14 payments
  7. LINZESS $263 27 payments
  8. STELARA $236 9 payments
  9. IMFINZI $233 2 payments
  10. DUPIXENT $222 8 payments
  11. Other $2,704 114 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

1,057

Median for Physician Assistant: 241

Drug cost

$251,452

Median for Physician Assistant: $4,110

Branded share of claims

32.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 62 $73,814
Relistor Methylnaltrexone Bromide Brand 19 $48,750
Motegrity Prucalopride Succinate Brand 27 $23,477
Ozempic Semaglutide Brand 22 $20,644
Trulance Plecanatide Brand 15 $18,044
Dexlansoprazole Dr Dexlansoprazole Brand 45 $16,591
Mounjaro Tirzepatide Brand 15 $14,955
Mesalamine Generic 35 $8,833
Lubiprostone Generic 44 $5,918
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 70 $4,512

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 12 billing codes

Paid by Medicare

$12,187

Medicare's payments for the services billed

Medicare patients

128

Average age 73

Services billed

168

77 women, 51 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 45%
Depression 34%
Chronic kidney disease 32%
Atrial fibrillation 28%
Diabetes 27%
Ischemic heart disease 26%
Cancer 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $206
$206 — —
LINZESS
  • Ironwood Pharmaceuticals, Inc $164
  • AbbVie, Inc. $26
$190 62 —
IBSRELA
  • Ardelyx, Inc. $174
$174 — —
REZDIFFRA
  • Madrigal Pharmaceuticals $139
$139 — —
DUPIXENT
  • GENZYME CORPORATION $112
$112 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

233 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record